Shanghai authorities fired neuroscientist Zilong Qiu and a Xinhua Hospital researcher following an investigation into the March 2025 death of a six-year-old girl during an experimental gene-editing trial. Regulators found that the team ignored preclinical primate toxicology warnings showing liver damage, failed to disclose the death in a publication, and received approval from Xinhua Hospital's ethics committee without providing required safety data.
Penalties for researchers and institutions
- ▪Chinese authorities barred Zilong Qiu and a deputy researcher at Xinhua Hospital from participating in government science projects for five years and added them to a national research integrity breach database
- ▪Shanghai Jiao Tong University School of Medicine and Xinhua Hospital received official reprimands following the Shanghai municipal government's investigation into the fatal gene-editing trial led by Zilong Qiu
- ▪Shanghai authorities sacked Zilong Qiu from his role as deputy director of the Songjiang Research Institution and dismissed a deputy researcher at Xinhua Hospital following a government investigation
- ▪Xinhua Hospital removed the lead clinical researcher on Zilong Qiu's team from the position of head of research following findings from Shanghai's investigation that safety warnings were overlooked in Zilong Qiu's gene-editing trial
Safety and consent failures
- ▪A preclinical toxicology study on monkeys conducted one month prior to the trial showed liver damage, but Zilong Qiu's team failed to inform the clinical research head at Xinhua Hospital in a timely fashion
- ▪The Xinhua Hospital ethics committee approved Zilong Qiu's experimental gene-editing trial despite lacking requested safety materials and sufficient preclinical toxicology evidence
- ▪Informed consent disclosures provided to the patient's family by Xinhua Hospital failed to state death as a risk of the experimental gene therapy
Academic irregularities and paper omissions
- ▪The Shanghai municipal government's investigation into the fatal Shanghai gene-editing trial led by Zilong Qiu identified undisclosed conflicts of interest and other academic irregularities among the participating researchers
- ▪Researchers involved in Zilong Qiu's Shanghai gene-editing trial omitted disclosure of the child's death in a February 2026 research paper
Regulations on investigator-initiated trials
- ▪New Chinese regulations taking effect in May 2026 restricted investigator-initiated trials to top-tier hospitals and introduced stricter manufacturing standards and penalties
- ▪China's investigator-initiated trial framework allowed researchers to test experimental gene therapies in hospitals without direct supervision from national drug regulators
Story comments
Loading comments…